Data shows reduced intervention after use of PleuraFlow active clearance technology in cardiac surgery- ClearFlow

ClearFlow announced that positive clinical trial results were presented at the International Coronary Congress (ICC) 2017 annual meeting. This data stems from a trial evaluating the use of the PleuraFlow Active Clearance Technology (ACT) System to prevent retained blood complications in heart surgery patients. The primary endpoint of this study was reduction in the composite of retained blood syndrome, which includes any of the following interventions performed during index hospitalization and 30-days readmission: Re-exploration for bleeding, delayed sternal closure and pleural and pericardial interventions.

The results demonstrated a statistically significant reduction of interventions for retained blood syndrome by 60.4% in the treatment group, including a 70% reduction in thoracentesis, a 33.7% reduction of postoperative atrial fibrillation (POAF) and a 65.6% reduction in infections. As seen in prior clinical trials, patients treated with the PleuraFlow System also had a statistically significant reduction in their overall hospital length of stay (LOS) by 1 day.

The findings were presented by the study principal investigator, Dr. Yvon Baribeau, of Catholic Medical Center in Manchester, New Hampshire, in a presentation titled �Active Clearance of Chest Drains Reduces Retained Blood and ICU Resources after Off-Pump Coronary Artery Bypass Surgery.�